

6 March 2020

The Manager  
ASX Announcements  
Australian Securities Exchange  
Level 4  
20 Bridge Street  
Sydney NSW 2000

Dear Sir / Madam

**ASX Appendix 3Y**

The Company refers to the following public announcements:

- (a) On 3 March 2020, the Company confirmed the initiation of the pivotal study for soft tissue reconstruction with the enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, Arizona.
- (b) On 5 March 2020, the Company confirmed the initiation of a pivotal trial for the treatment of pediatric scald injuries with enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, Arizona.
- (c) The vesting of various restricted stock units for the Company's Chief Executive Officer, Dr Mike Perry, in connection with the achievement of the above corporate milestones (as confirmed by an ASX Appendix 2A released by the Company on each of the above dates).

Pursuant to the above, please find attached an ASX Appendix 3Y recording a change in Dr Perry's interests in the Company.

**Please note that the disposal (i.e. sale) of shares by Dr Perry as reflected in the attached ASX Appendix 3Y are sales executed solely for the purposes of satisfying Dr Perry's income tax liability payable to the U.S. Internal Revenue Service and various State tax authorities (i.e. all sales are solely to cover income tax liability).**

Authorized by

**David McIntyre**  
**Chief Financial Officer**

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>AVITA Medical Limited</b>
<b>ABN</b>	<b>28 058 466 523</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael Perry
<b>Date of last notice</b>	4 March 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	
<b>Date of change</b>	4 & 5 March 2020
<b>No. of securities held prior to change</b>	19,553,248 Ordinary Shares 46,592,658 Unlisted Restricted Stock Units, LTI Plan 15,000,000 Unlisted Options
<b>Class</b>	Ordinary Shares; and Unlisted Restricted Stock Units, LTI Plan (RSU's)
<b>Number acquired</b>	6,850,484 Ordinary Shares
<b>Number disposed</b>	6,434,219 Ordinary Shares; and 6,850,484 RSU's

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Acquisition of 6,850,484 ordinary shares - Nil consideration, issued as part of conversion of Director's RSU's  Disposal of 3,258,044 shares - \$ 0.6248 per share Disposal of 3,176,175 shares - \$0.6169 per share
<b>No. of securities held after change</b>	19,969,513 Ordinary Shares 39,742,174 Unlisted Restricted Stock Units, LTI Plan 15,000,000 Unlisted Options
<b>Nature of change</b> <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Acquisition - Conversion of Unlisted Restricted Stock Units, LTI Plan  Disposal - On market sale

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Not applicable
<b>Nature of interest</b>	Not applicable
<b>Name of registered holder (if issued securities)</b>	Not applicable
<b>Date of change</b>	Not applicable
<b>No. and class of securities to which interest related prior to change</b> <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	Not applicable
<b>Interest acquired</b>	Not applicable
<b>Interest disposed</b>	Not applicable
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	Not applicable
<b>Interest after change</b>	Not applicable

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	Not applicable
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

+ See chapter 19 for defined terms.